- One dose of Sputnik-V can build more immunity against corona
- COVID-19 is caused by SARS-CoV-2 virus and Sputnik V is effective in this.
- Two doses of ‘Sputnik-V’ were found to make 92 percent immunity.
A single dose of the anti-coronavirus vaccine ‘Sputnik-V’ can create greater immunity against SARS-CoV-2. This has been revealed in a study. COVID-19 is caused by the SARS-CoV-2 virus. Earlier in a study, two doses of ‘Sputnik-V’ were found to create 92 percent immunity against Kovid-19. ‘Sputnik-V’ is produced by combining two ‘adenoviruses’.
These are viruses that cause a variety of diseases, including cold, fever and sore throat. A new study, published Tuesday in the journal Cell Reports Medicine, sought to find out whether a single dose of the vaccine could have more public health benefits than two doses, allowing a larger population to be treated as quickly as possible. Vaccines can be made.
Need to compile data related to immunity
Andrea Gamarnik of the Fundación Instituto Leloir-Coniquet in Buenos Aires, Argentina, senior author of the study, said: “Due to limited vaccine supplies and uneven vaccine distribution in many regions of the world, health authorities need to adapt vaccination strategies. There is an urgent need to compile data related to the immunity of vaccines for this purpose.
“The peer-reviewed data we present provide information to guide public health decisions in the current global health emergency,” he said. In the new study, researchers compared the immunity against SARS-CoV-2 of a single dose of ‘Sputnik-V’ and two doses of ‘Sputnik-V’ on 289 healthcare workers.
90% evidence of neutralizing ‘antibodies’
After the first dose, 94 percent of these participants developed ‘immunoglobulin G (IgG) antibodies’ against the virus and 90 percent showed evidence of neutralizing ‘antibodies’, which affect the ability of the virus to infect cells. intervene. The research found that previously infected participants had significantly higher levels of IgG and ‘neutralizing antibodies’ after a single dose than those who did not get the infection.
At the same time, the second dose did not increase the production of neutralizing antibodies in those already infected. He said that high immunity levels after one dose to these people suggests a delayed administration of the second dose, so that more people can get the vaccine as soon as possible.